NetworkNewsBreaks – Vivos Therapeutics Inc. (NAS
Post# of 51
(Total Views: 231)
Posted On: 08/18/2021 5:17:54 PM
NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Detailed Summary of National Study
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in the study who used Vivos’ FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms; that is officially defined as patients in post treatment having an Apnea Hypopnea Index (“AHI”) score of less than 5. According to the announcement, before the study, 20 patients had severe OSA. Following the study, none of the patients reported worsening of their OSA symptoms, with 3 still reporting severe OSA, 12 reporting moderate OSA, 4 reporting mild OSA and 1 reporting no OSA. Of the 18 patients who began the study with moderate OSA, 64% reported an average percent improvement in AHI score. “By addressing maxillary palatal deficiencies, we believe Vivos’ treatment protocols represent an improvement over CPAP and mandibular advancement devices, known as MAD, with 27% of the study participants reporting a complete resolution of their OSA symptoms,” said Vivos chair and CEO Kirk Huntsman in the press release. “These measurements are taken without a Vivos appliance in the mouth, whereas MAD measurements are taken with the appliance in place. The more detailed data now available from this study confirms that the Vivos device works well for many patients, with the study showing very strong and statistically significant evidence for an increase in airway volume and transpalatal width (p<0.00001). We know the investment community and other interested parties have been looking for more real-world data about our devices, so we are pleased to share this more detailed study summary and its positive results.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in the study who used Vivos’ FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms; that is officially defined as patients in post treatment having an Apnea Hypopnea Index (“AHI”) score of less than 5. According to the announcement, before the study, 20 patients had severe OSA. Following the study, none of the patients reported worsening of their OSA symptoms, with 3 still reporting severe OSA, 12 reporting moderate OSA, 4 reporting mild OSA and 1 reporting no OSA. Of the 18 patients who began the study with moderate OSA, 64% reported an average percent improvement in AHI score. “By addressing maxillary palatal deficiencies, we believe Vivos’ treatment protocols represent an improvement over CPAP and mandibular advancement devices, known as MAD, with 27% of the study participants reporting a complete resolution of their OSA symptoms,” said Vivos chair and CEO Kirk Huntsman in the press release. “These measurements are taken without a Vivos appliance in the mouth, whereas MAD measurements are taken with the appliance in place. The more detailed data now available from this study confirms that the Vivos device works well for many patients, with the study showing very strong and statistically significant evidence for an increase in airway volume and transpalatal width (p<0.00001). We know the investment community and other interested parties have been looking for more real-world data about our devices, so we are pleased to share this more detailed study summary and its positive results.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)